SUVEN Life Sciences

Communication to investors
Sept 2011

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW
Quarter 2 – Sept 2011

• Growth in revenue	31.17%
• Growth in PAT	9.77%
• Growth in EBIDTA	22.64%
• Growth in Pre-R&D EBIDTA	13.56%
• Increase in R&D costs	9.85%
• R&D cost on revenue	17.66%


FINANCIAL QUICK VIEW
Half year – Sept 2011

• Growth in revenue	27.41%
• Growth in PAT	2.47%
• Growth in EBIDTA	19.32%
• Growth in Pre-R&D EBIDTA	9.11%
• Increase in R&D costs	3.71%
• R&D cost on revenue	17.20%


MAJOR PROFITABILITY RATIOS

	Q2 Sept 11	Q2 Sept 10	HY Sep 11	HY Sep 10
PAT to Income	5.16%	6.16%	6.27%	7.79%
EBIDTA to Income	8.07%	8.63%	9.93%	10.55%
Cash Flow to Income	7.98%	9.77%	9.22%	11.44%
Pre-R&D EBITDA to Income	25.73%	29.72%	27.12%	31.67%

INCOME COMPARISON




PROFIT COMPARISON




PAT for qtr ending Sep2011 is after provision for MTM of Rs. 54.2 Million towards forward contracts due to exchange fluctuation


EBIDTA COMPARISON




R & D – EXPENDITURE



PRE-R&D EBIDTA




PRE-R&D CASHFLOW



Updates for the quarter

- **During the quarter there were major qualitative achievements with the grant of 8 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules current**ly in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to develop**mental candidate SUVN-502 for Alzheimer's disease and Schizophrenia**
- **Also** during the quarter Suven bagged **Pharmexcil's "Patent Award"** for securing the most number of product patents during 2010/11 for their New Chemical Entities (NCE's) **under Gold Category** third y**ear in a row. The A**wards were presented during the "Awards Function during India-LAC Pharma Business Meet" organized by Pharmexcil and by Dept Commerce, Govt of India.

SUVEN an end to end bio-pharmaceutical solutions company



Collaborative Research Partner (CRP) …

Seamless transition

2011-12 Q2 results